

# Claudia Bracaglia

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7101876/claudia-bracaglia-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68  
papers

2,074  
citations

24  
h-index

45  
g-index

88  
ext. papers

2,684  
ext. citations

5  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
68	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFN $\gamma$ ) Monoclonal Antibody. <i>Blood</i> , <b>2021</b> , 138, 2058-2058	2.2	0
67	Targeting interferon- $\gamma$ in hyperinflammation: opportunities and challenges. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 678-691	8.1	5
66	Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	5
65	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	14
64	Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 663329	8.4	3
63	Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. <i>Pediatric Rheumatology</i> , <b>2021</b> , 19, 29	3.5	22
62	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 1043-1051	6.9	2
61	Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	3
60	IgM on the surface of T cells: a novel biomarker of pediatric-onset systemic lupus erythematosus. <i>Pediatric Nephrology</i> , <b>2021</b> , 36, 909-916	3.2	1
59	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 898-906	4.1	2
58	Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria. <i>Rheumatology</i> , <b>2021</b> , 60, 3144-3155	3.9	5
57	Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1053-1061	9.5	8
56	Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. <i>Italian Journal of Pediatrics</i> , <b>2021</b> , 47, 24	3.2	28
55	Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e563-e573	14.2	3
54	Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children. <i>Blood Purification</i> , <b>2021</b> , 1-8	3.1	0
53	Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. <i>Journal of Pediatrics</i> , <b>2021</b> , 235, 196-202	3.6	1
52	CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REAL-LIFE DATA FROM A RETROSPECTIVE ITALIAN COHORT. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1

51	Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. <i>Pediatric Rheumatology</i> , <b>2021</b> , 19, 144	3.5	0
50	A patient with stimulator of interferon genes-associated vasculopathy with onset in infancy without skin vasculopathy. <i>Rheumatology</i> , <b>2020</b> , 59, 905-907	3.9	5
49	Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis. <i>Frontiers in Genetics</i> , <b>2020</b> , 11, 937	4.5	6
48	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 3505-3514	3.9	16
47	Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 523-526	4.1	17
46	An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. <i>Pediatric Rheumatology</i> , <b>2019</b> , 17, 25	3.5	5
45	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 2778-2799	16.6	71
44	FRI0565 A MULTINATIONAL STUDY OF THROMBOTIC MICROANGIOPATHY IN MACROPHAGE ACTIVATION SYNDROME: A DREADFUL CONDITION WHICH IS LIKELY UNDER-RECOGNIZED <b>2019</b> ,		2
43	The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0226043	3.7	12
42	Interleukin-18 in pediatric rheumatic diseases. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 421-427	5.3	11
41	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1526	5.6	6
40	Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1167-1172	4.1	35
39	Neutralization of IFN- $\gamma$ Reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 1439-1449	11.5	64
38	Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 5	3.5	92
37	Elevated circulating levels of interferon- $\beta$ and interferon- $\beta$ -induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 166-172	2.4	154
36	ANCA-associated vasculitis in childhood: recent advances. <i>Italian Journal of Pediatrics</i> , <b>2017</b> , 43, 46	3.2	44
35	Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 822-826	4.1	15
34	Use of a mouse model to identify a blood biomarker for IFN- $\beta$ activity in pediatric secondary hemophagocytic lymphohistiocytosis. <i>Translational Research</i> , <b>2017</b> , 180, 37-52.e2	11	35

33	Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2017</b> , 31, 505-516	5.3	32
32	Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis. <i>Journal of the Pediatric Infectious Diseases Society</i> , <b>2016</b> , 5, 76-9	4.8	4
31	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet, The</i> , <b>2016</b> , 387, 671-678	4.0	124
30	A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. <i>Journal of Immunology</i> , <b>2016</b> , 196, 2492-503	5.3	58
29	Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1523-7	4.1	39
28	Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13,	3.5	2
27	FRI0323 Chronic Non-Bacterial Osteomyelitis (CNO) in a Cohort of Pediatric Patients: Clinical, Biological and Radiological Response to Treatment with Anakinra. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 541.2-541	2.4	
26	OP0066 Safety of Anti-TNF $\alpha$ Agents for the Treatment of Juvenile Idiopathic Arthritis-Related Uveitis: Data from the Orchidea Registry. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 93.1-93	2.4	2
25	Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 3037-46	9.5	153
24	S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13,	3.5	2
23	Anti interferon-gamma (IFN $\gamma$ ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13,	3.5	8
22	High levels of interferon-gamma (IFN $\gamma$ ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFN $\gamma$ production in MAS. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13,	3.5	3
21	Chronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra. <i>Pediatric Rheumatology</i> , <b>2015</b> , 13,	3.5	78
20	Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120981	3.7	29
19	Renal involvement in hypocomplementaemic urticarial vasculitis syndrome: a report of three paediatric cases. <i>Rheumatology</i> , <b>2014</b> , 53, 1409-13	3.9	12
18	Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). <i>Pediatric Rheumatology</i> , <b>2014</b> , 12,	3.5	19
17	Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. <i>Pediatric Rheumatology</i> , <b>2014</b> , 12, P56	3.5	5
16	Interferon-gamma (IFN $\gamma$ ) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model. <i>Pediatric Rheumatology</i> , <b>2014</b> , 12,	3.5	6

15	Predictors of relapse after discontinuing systemic treatment in autoimmune chronic uveitis. <i>Pediatric Rheumatology</i> , <b>2014</b> , 12,	3.5	78
14	Clinical presentation and cytokine production abnormalities in a cohort of patients carrying NLRP12 gene variants. <i>Pediatric Rheumatology</i> , <b>2014</b> , 12, P71	3.5	78
13	MRI assessment of tenosynovitis in children with juvenile idiopathic arthritis: inter- and intra-observer variability. <i>Pediatric Radiology</i> , <b>2013</b> , 43, 796-802	2.8	18
12	Necrosis of the tongue as first symptom of Polyarteritis Nodosa (PAN): unusual presentation of a rare disease in children. <i>Rheumatology International</i> , <b>2013</b> , 33, 1071-3	3.6	6
11	Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome. <i>Rheumatology International</i> , <b>2013</b> , 33, 1097-8	3.6	9
10	Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 74-9	4.1	125
9	MRI of the wrist in juvenile idiopathic arthritis: proposal of a paediatric synovitis score by a consensus of an international working group. Results of a multicentre reliability study. <i>Pediatric Radiology</i> , <b>2012</b> , 42, 1047-55	2.8	28
8	MRI assessment of bone marrow in children with juvenile idiopathic arthritis: intra- and inter-observer variability. <i>Pediatric Radiology</i> , <b>2012</b> , 42, 714-20	2.8	22
7	Longitudinal myelitis in systemic lupus erythematosus: a paediatric case. <i>Rheumatology International</i> , <b>2012</b> , 32, 2587-8	3.6	6
6	Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1287-90	4.1	29
5	Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. <i>Rheumatology International</i> , <b>2011</b> , 31, 93-5	3.6	23
4	EULAR/PRINTO/PRES criteria for Henoch-Schleien purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 790-7	2.4	140
3	Relapsing polychondritis: new therapeutic strategies with biological agents. <i>Rheumatology International</i> , <b>2010</b> , 30, 691-3	3.6	24
2	Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study. <i>Journal of Pediatrics</i> , <b>2010</b> , 156, 972-977	3.6	24
1	Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 3388-99		192